310 related articles for article (PubMed ID: 15644871)
21. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
Auclair B; Mikota SK; Peloquin CA; Aguilar R; Maslow JN
J Zoo Wildl Med; 2002 Sep; 33(3):193-203. PubMed ID: 12462485
[TBL] [Abstract][Full Text] [Related]
23. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
[TBL] [Abstract][Full Text] [Related]
24. Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.
Schwartz YS; Dushkin MI; Vavilin VA; Melnikova EV; Khoschenko OM; Kozlov VA; Agafonov AP; Alekseev AY; Rassadkin Y; Shestapalov AM; Azaev MS; Saraev DV; Filimonov PN; Kurunov Y; Svistelnik AV; Krasnov VA; Pathak A; Derrick SC; Reynolds RC; Morris S; Blinov VM
Antimicrob Agents Chemother; 2006 Jun; 50(6):1982-8. PubMed ID: 16723555
[TBL] [Abstract][Full Text] [Related]
25. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.
Hwang JM; Oh T; Kaneko T; Upton AM; Franzblau SG; Ma Z; Cho SN; Kim P
J Nat Prod; 2013 Mar; 76(3):354-67. PubMed ID: 23360475
[TBL] [Abstract][Full Text] [Related]
27. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of highly potent novel anti-tubercular isoniazid analogues with preliminary pharmacokinetic evaluation.
Ramani AV; Monika A; Indira VL; Karyavardhi G; Venkatesh J; Jeankumar VU; Manjashetty TH; Yogeeswari P; Sriram D
Bioorg Med Chem Lett; 2012 Apr; 22(8):2764-7. PubMed ID: 22440626
[TBL] [Abstract][Full Text] [Related]
29. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Hearn MJ; Cynamon MH
Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
[TBL] [Abstract][Full Text] [Related]
31. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
32. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
33. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Nikonenko BV; Samala R; Einck L; Nacy CA
Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and anti-mycobacterial activity of novel amino alcohol derivatives.
Cunico W; Gomes CR; Ferreira ML; Ferreira TG; Cardinot D; de Souza MV; Lourenço MC
Eur J Med Chem; 2011 Mar; 46(3):974-8. PubMed ID: 21295888
[TBL] [Abstract][Full Text] [Related]
35. [Experimental study on the antituberculous activity of ofloxacins].
Duan L; Liang G; Li H
Zhonghua Jie He He Hu Xi Za Zhi; 1997 Apr; 20(2):98-100. PubMed ID: 10072834
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel [1,2]-diamines with antituberculosis activity.
Meng Q; Luo H; Chen Y; Wang T; Yao Q
Bioorg Med Chem Lett; 2009 Sep; 19(18):5372-5. PubMed ID: 19682895
[TBL] [Abstract][Full Text] [Related]
37. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
Dekker TG; Lötter AP
Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
[No Abstract] [Full Text] [Related]
38. Interspecies pharmacokinetics and in vitro metabolism of SQ109.
Jia L; Noker PE; Coward L; Gorman GS; Protopopova M; Tomaszewski JE
Br J Pharmacol; 2006 Mar; 147(5):476-85. PubMed ID: 16432511
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.
Onajole OK; Govender P; van Helden PD; Kruger HG; Maguire GE; Wiid I; Govender T
Eur J Med Chem; 2010 May; 45(5):2075-9. PubMed ID: 20149497
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacodynamics and pharmacokinetics of domestic fixed-dose combination of antituberculosis drugs].
Zhao W; Li H; Duan L; Liang G; Zhang T; Lu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):333-6. PubMed ID: 12126555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
